Model iPSC-derived -Mesenchymal Stem/Stromal Cells (Msc)

Mesenchymal stem/stromal cells (MSC) have undergone extensive clinical testing for many diseases and have consistently demonstrated safety. In addition, the immunomodulatory properties of MSC have been well characterized. However, adult-tissue-derived MSC have shown inconsistent therapeutic efficacy, significant variability among samples, and limited proliferative capacity. On the other hand, MSC derived from iPSCs (iMSC) offer a near limitless supply of cells due to their superior expansion potential. Our data shows improved therapeutic properties and greater consistency of iMSC relative to adult-derived MSC.